Newly Diagnosed Multiple Myeloma
Oncology·MeSH: Multiple Myeloma
Prevalence
17.0 / 100K
Incidence
7.0 / 100K/yr
6 drugs in development·4 companies·3 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| thalomid | CELGENE CORP /DE/ (CELG) |
Phase 2(4)
Phase 1(1)
| Drug | Company |
|---|---|
| TAK-079 | Merus N.V. (MRUS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Newly Diagnosed Multiple Myeloma?
BioSniper tracks 6 drugs in development for Newly Diagnosed Multiple Myeloma across 4 companies.
How many clinical trials target Newly Diagnosed Multiple Myeloma?
There are 3 clinical trials targeting Newly Diagnosed Multiple Myeloma tracked by BioSniper.
What is the prevalence of Newly Diagnosed Multiple Myeloma?
The estimated prevalence of Newly Diagnosed Multiple Myeloma is approximately 17.0 per 100,000 population.
Deep-dive into Newly Diagnosed Multiple Myeloma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis